American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options
Lowell E. Schnipper(Fox Chase Cancer Center), Richard L. Schilsky(American Society of Clinical Oncology), Therese M. Mulvey(Sidney Kimmel Cancer Center), Dana S. Wollins(Infectious Diseases Society of America), Leonard B. Saltz(Memorial Sloan Kettering Cancer Center), Nancy E. Davidson(WinnMed), Clifford A. Hudis(American Society of Clinical Oncology), Adam P. Dicker(Thomas Jefferson University Hospital), Neal J. Meropol(Flatiron Health (United States)), Thomas J. Smith(Sidney Kimmel Cancer Center), Lee N. Newcomer(Sidney Kimmel Cancer Center), Derek Raghavan(United States Department of Veterans Affairs), Douglas W. Blayney(Stanford University), Blasé N. Polite(Sidney Kimmel Cancer Center), Gary H. Lyman(University of Washington), Courtney Tyne(Einstein Healthcare Network), J. Russell Hoverman(Texas Oncology), Deborah Schrag(Dana-Farber Brigham Cancer Center), Peter Paul Yu(Sidney Kimmel Cancer Center), Patricia A. Ganz(Los Angeles County Department of Public Health), Gregory Rossi(Sidney Kimmel Cancer Center), Jeffrey Peppercorn(Stem Cell Institute), Diane Blum(Sidney Kimmel Cancer Center), Robert M. Langdon(Sidney Kimmel Cancer Center)
Cited by 903
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
How To Build and Interpret a Nomogram for Cancer Prognosis
|Journal of Clinical Oncology|2008|3.4k
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k